Anthracycline
Sponsors
AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Kronos Bio, Guangdong Provincial People's Hospital
Conditions
Acute Myeloid Leukaemia (AML)Acute Myeloid Leukemia (AML)Advanced Breast CancerBreast CancerBreast NeoplasmsHER2-negative Breast CancerLeukemia, Myeloid, AcuteNucleophosmin 1-mutated Acute Myeloid Leukemia
Phase 1
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
TerminatedNCT02561832
Start: 2015-11-06End: 2017-02-01Updated: 2019-02-20
HDM201 Added to CT in R/R or Newly Diagnosed AML
WithdrawnNCT03760445
Start: 2019-11-15End: 2023-06-13Updated: 2020-01-09
Phase 2
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
RecruitingNCT06102824
Start: 2024-10-01End: 2028-06-30Target: 252Updated: 2024-11-25
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
RecruitingNCT06802757
Start: 2025-05-01End: 2028-02-01Target: 72Updated: 2026-02-25
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
Not yet recruitingNCT07060001
Start: 2026-04-01End: 2029-12-01Target: 112Updated: 2026-03-06
Phase 3
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
CompletedNCT04109066
Start: 2019-11-18End: 2023-12-27Updated: 2025-01-08
Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
TerminatedNCT05020665
Start: 2021-11-24End: 2023-03-30Updated: 2024-01-10